Founder and CEO
ShiYin Foo is the scientific founder and CEO of Arvada Therapeutics. She is a cardiologist and immunologist with over 20 years of experience as a practicing physician and a catalyst in advancing innovative new programs through the various stages of drug development. She has been in executive roles at multiple biotechnology companies, including Cardioxyl Pharmaceuticals, Imara Therapeutics, Tiburio Therapeutics and Cydan II, and is currently on the Board of Directors at Thryv Therapeutics. ShiYin received her MD and PhD in Immunology from Stanford University, and a MMSc in Clinical Science from the Clinical Investigator Training Program at Harvard Medical School. She was clinical faculty at the Massachusetts General Hospital and Harvard Medical School, and a dual Diplomate of the American Board of Internal Medicine and in Cardiology.
Co-founder and SVP of Preclinical Research
Ryan Tyler is the SVP of Preclinical Research and a cofounder at Arvada Therapeutics. He is a molecular and cellular biologist with broad industry experience in preclinical research, spanning early drug discovery to IND in the areas of rare and degenerative diseases. Prior to Arvada, Ryan was Vice President of Preclinical Research at the orphan drug accelerator Cydan II, Inc. He has held leadership roles at Amathus Therapeutics and at Proteostasis Therapeutics, where he established new discovery programs and led preclinical activities that enabled the initiation of clinical programs for cystic fibrosis. Ryan began his industry career at Pfizer, where he led the development of biomarker assays and translational models for cystic fibrosis drug discovery. Ryan was a postdoctoral scholar at Stanford University and received his doctorate in Microbiology and Immunology from the University of Michigan.